Acetyl Octapeptide-3
Evidence Grade E — Very limited evidence. 0 published studies. 0 registered clinical trials.
SNAP-8 is an eight-amino-acid extension of Argireline, developed as a more potent version for cosmetic wrinkle reduction. At 1,075 Da, it is even larger than Argireline and faces greater challenges penetrating intact skin to reach its target. It faces a fundamental paradox: increased laboratory potency is offset by decreased ability to get through the skin. It has no pharmaceutical approval.
No published studies found on PubMed.
SNAP-8 has no pharmaceutical authorisation. It is used as a cosmetic ingredient. An industry-sponsored open-label study (17 subjects) reported wrinkle reduction, with a maximum individual result of 63% — though this was a single-subject maximum, not a study average.
SNAP-8 illustrates a recurring challenge with cosmetic peptides: increased potency in laboratory assays does not address the fundamental question of whether the molecule can penetrate skin in sufficient quantities to reach its target. It is a topical cosmetic ingredient.
Research suggests SNAP-8 works through the same SNARE complex inhibition mechanism as Argireline but with approximately twice the potency in laboratory assays. However, its larger molecular size (1,075 Da versus 889 Da for Argireline) makes skin penetration to the target neuromuscular junctions even less likely than for its predecessor.
Research consists of a single manufacturer study (17 subjects, open-label design). The claimed 63% wrinkle reduction was a single-subject maximum, not a study average. Claimed superiority over Argireline is based on historical comparison rather than head-to-head testing. At 1,075 Da, SNAP-8 substantially exceeds the generally accepted 500 Da skin penetration threshold — even more so than Argireline (889 Da). No independent peer-reviewed clinical trials exist. It is a topical cosmetic ingredient.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
Epitalon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. Animal lifespan studies in mice reported by the Khavinson group form the core evidence base. The telomerase activation claims are based on in vitro studies and mouse models from a single research programme. Independent replication of the key findings has not been published. The relationship between in vitro telomerase activation and any clinical outcome in humans is not established. Products available through unregulated channels lack pharmaceutical quality assurance.
FOXO4-DRI has no marketing authorisation. No human clinical trials have been conducted. The evidence comes from a single high-profile publication (Cell, 2017) demonstrating effects in three mouse models. The senolytic field is an active area of pharmaceutical research, but FOXO4-DRI faces significant challenges for clinical translation, including its large size (46 amino acids), manufacturing complexity, and the absence of human pharmacokinetic or safety data. Products available through unregulated channels — which would need to reliably synthesise a 46-amino-acid all-D-amino-acid peptide — face exceptional quality assurance challenges.
